Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 743 of 5804
-
New hope for lung cancer patients: lorlatinib shows promise in Real-World study
Disease control CompletedThe purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled. This study is seeking participants who: * have lung cancer that could not be controlled. * have a type of gene called anaplastic lymphoma kinase. A ge…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could an Immune-Modulating drug slow early Alzheimer's?
Disease control CompletedAccumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing o…
Phase: PHASE2 • Sponsor: St. Joseph's Hospital and Medical Center, Phoenix • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New heart device could rival surgery for leaky valve patients
Disease control OngoingThe objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by …
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for pregnant women battling opioid addiction: monthly shot vs daily pill
Disease control CompletedThe primary objective of this study is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and infant outcomes. The primary hypothesis is that the BUP…
Phase: PHASE3 • Sponsor: T. John Winhusen, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo trial launches
Disease control Recruiting nowThis research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved i…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug aims to tame rare blood disorder flares
Disease control OngoingThis is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study compr…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo aims to keep lung cancer in check
Disease control OngoingThis phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, m…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
R2D2 trial: deprescribing anticholinergics may shield aging brains
Prevention OngoingA cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.
Phase: NA • Sponsor: Indiana University • Aim: Prevention
Last updated Jun 27, 2026 12:07 UTC
-
New radiation therapy shows promise for slowing prostate cancer spread
Disease control CompletedRadioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. In…
Phase: PHASE2 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental combo therapy shows promise for Tough-to-Treat lymphomas
Disease control CompletedThis phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer \[NK\] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma th…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Radiation boosts liver size, paving way for cancer surgery
Disease control OngoingHCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with…
Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis phase I/II trial studies the side effects and best dose of copanlisib when given together with nivolumab and ipilimumab and to see how well they work in treating patients with solid cancers that may have spread from where it first started to nearby tissue, lymph nodes, or di…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could timed light therapy save more premature babies?
Disease control OngoingCycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (\< 750 g BW or \<27 weeks GA).
Phase: NA • Sponsor: NICHD Neonatal Research Network • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lung-Directed chemo spray aims to stop cancer spread
Disease control Recruiting nowThis phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cispla…
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail aims to shrink lymphoma without chemo
Disease control OngoingThis phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dru…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill combo aims to keep advanced breast cancer in check
Disease control OngoingThe purpose of this two part multicenter, randomized, double-blind, placebo-controlled, Phase III study is to evaluate the efficacy and safety of alpelisib compared to alpelisib matching-placebo in combination with trastuzumab and pertuzumab as maintenance treatment of patients w…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare, deadly gynecologic cancers: drug combo trial launches
Disease control Recruiting nowCarcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \< 10% and a poor…
Phase: PHASE2, PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aimed at folate receptor shows promise for tough endometrial cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Phase: PHASE2 • Sponsor: Alessandro Santin • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy shows promise for advanced skin cancer patients
Disease control CompletedThe purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in Chinese participants with no prior systemic t…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for MS patients: ofatumumab cuts relapses in switchers
Disease control CompletedOpen-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC